Research programme: dopamine D2 receptor antagonists - Pierre Fabre
Latest Information Update: 14 Dec 2006
At a glance
- Originator Pierre Fabre
- Mechanism of Action Dopamine D2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psychotic disorders
Most Recent Events
- 10 Jul 2001 No-Development-Reported for Psychotic disorders in France (Unknown route)
- 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance
- 21 Oct 1998 New profile